rs1801155 — APC I1307K

Missense variant in the APC tumor suppressor that creates a hypermutable poly-A tract, increasing somatic mutation rate and colorectal cancer risk approximately 1.5-2 fold — strongly enriched in Ashkenazi Jewish populations (~6% carrier frequency)

See your personal result for APC

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

APC I1307K — A Silent Architect of Colorectal Cancer Risk

The APC gene encodes a massive tumor suppressor protein that acts as a gatekeeper of intestinal epithelial cell proliferation11 intestinal epithelial cell proliferation
APC restrains the Wnt signaling pathway by targeting beta-catenin for degradation; when APC is lost, beta-catenin accumulates and drives uncontrolled cell growth. Loss of APC function is the initiating event in most colorectal cancers — both inherited and sporadic. The I1307K variant does not directly disable the APC protein. Instead, it rewires a short stretch of the gene's DNA into a molecular trap that catches replication errors, quietly accelerating the rate at which APC can be knocked out in colon cells.

First identified in 1997 by Laken and colleagues at Johns Hopkins22 Laken and colleagues at Johns Hopkins
The team discovered I1307K while investigating Ashkenazi Jewish families with unexplained clustering of colorectal cancer, this variant is carried by approximately 6% of people of Ashkenazi Jewish descent — one of the highest population-specific carrier frequencies for any cancer susceptibility allele. Outside Ashkenazi populations, the allele is rare (1-2% in Europeans overall, essentially absent in East Asian and African populations).

The Mechanism

The I1307K variant is a T-to-A transversion at nucleotide 3920 of the APC coding sequence, changing isoleucine to lysine at codon 1307. The protein change itself is functionally neutral — lysine at position 1307 does not impair APC's ability to degrade beta-catenin or suppress Wnt signaling. The danger lies entirely at the DNA level.

The normal APC sequence around codon 1307 contains a T4A4 motif. The I1307K transversion converts this into an uninterrupted A8 homopolymer tract33 A8 homopolymer tract
A run of eight consecutive adenine nucleotides; homopolymer tracts are inherently difficult for DNA polymerase to replicate accurately because the repetitive sequence promotes strand slippage. During DNA replication, polymerase is prone to slipping on this extended A-run, inserting or deleting one or more adenines. A single-nucleotide insertion at this site shifts the reading frame, truncating the APC protein and eliminating its tumor suppressor function in that cell.

Gryfe et al. demonstrated44 Gryfe et al. demonstrated
Cancer Research, 1998: tumors from 127 I1307K carriers were analyzed for somatic mutations at the variant tract that 42% of colorectal tumors in I1307K carriers harbor somatic frameshift mutations originating at the A8 tract — a 10-fold enrichment compared to the same region in non-carriers. The mechanism is elegant and insidious: the germline variant does not cause cancer directly, but it dramatically increases the probability that APC will be somatically inactivated in colonic epithelial cells over a lifetime.

The Evidence

The original discovery55 original discovery
Laken SJ et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genetics, 1997 identified I1307K in 6% of Ashkenazi Jews and approximately 28% of Ashkenazi families with a strong history of colorectal cancer.

A HuGE meta-analysis of 40 studies66 HuGE meta-analysis of 40 studies
Liang et al. APC polymorphisms and the risk of colorectal neoplasia. American Journal of Epidemiology, 2013 calculated a pooled odds ratio of 2.17 (95% CI 1.64-2.86) for colorectal neoplasia in Ashkenazi Jewish I1307K carriers. In a large Israeli screening cohort77 large Israeli screening cohort
Boursi et al. European Journal of Cancer, 2013; 3,305 individuals undergoing colonoscopy, the adjusted odds ratio was 1.75 (95% CI 1.26-2.45) for colorectal cancer among average-risk Ashkenazi carriers.

The risk appears to operate primarily at the adenoma-to-carcinoma transition rather than adenoma formation itself. Stern et al.88 Stern et al.
Gastroenterology, 2001 found that I1307K was present in 27% of Ashkenazi Jewish colorectal cancer survivors versus only 8% of asymptomatic controls, while adenomatous polyp prevalence was similar between carriers and non-carriers. This suggests the variant accelerates malignant transformation of existing polyps rather than polyp initiation.

Recent evidence extends beyond Ashkenazi populations. A 2022 analysis of over 200,000 individuals99 2022 analysis of over 200,000 individuals
Forkosh et al. Cancers, 2022 found that non-Ashkenazi white I1307K carriers also face elevated cancer risk, with odds ratios of 1.95 for colorectal cancer and notable associations with melanoma (OR 2.54) and prostate cancer (OR 2.42 in males).

Practical Implications

The I1307K variant places carriers in a moderate-risk category for colorectal cancer — higher than population average but far below the near-certainty of classic familial adenomatous polyposis (caused by truncating APC mutations). The primary actionable consequence is intensified colonoscopic surveillance. Current expert consensus1010 Current expert consensus
Breen et al. Genetics in Medicine, 2022 recommends initiating colonoscopy at age 40 for I1307K carriers, with repeat screening every 5 years — roughly 5 years earlier and more frequently than standard-risk guidelines.

Because the variant is overwhelmingly concentrated in the Ashkenazi Jewish population, carrier status also informs family screening: first-degree relatives of a carrier each have a 50% chance of carrying the same allele and may benefit from targeted testing.

Aspirin and NSAID chemoprevention may have particular relevance for I1307K carriers, as these agents reduce colorectal adenoma recurrence in moderate-risk populations. However, the decision to use long-term aspirin requires balancing gastrointestinal bleeding risk and should be discussed with a gastroenterologist in the context of individual risk factors.

Interactions

The colorectal cancer risk landscape involves multiple loci. The 8q24 risk variant rs6983267 is one of the most replicated CRC GWAS signals, with per-allele OR of approximately 1.2. Carriers of both I1307K and the rs6983267 risk allele may have compounded colorectal cancer risk, though no formal interaction study has quantified the combined effect specifically.

MLH1 promoter methylation, tagged by rs1800734, is the primary cause of sporadic microsatellite-instable colorectal cancer. In theory, I1307K carriers whose tumors also acquire MLH1 silencing face a double hit — increased somatic mutation rate at APC plus defective mismatch repair — but this interaction has not been formally studied at the germline level.

Genotype Interpretations

What each possible genotype means for this variant.

TT Non-carrier Normal

Normal APC sequence — no hypermutable tract at codon 1307

You carry two copies of the common T allele at rs1801155, meaning your APC gene retains the normal T4A4 motif around codon 1307. This is the most common genotype worldwide, found in approximately 94% of people overall and 88% of people of Ashkenazi Jewish descent. Your APC gene does not carry the I1307K hypermutability variant, and your baseline colorectal cancer risk from this locus is not elevated.

AA I1307K Homozygous High Risk

Two copies of I1307K — both APC alleles carry the hypermutable tract, likely further elevating colorectal cancer risk

Homozygosity for I1307K means both chromosomal copies of APC contain the A8 homopolymer tract. In Knudson's two-hit model of tumor suppression, cancer initiation requires inactivation of both APC copies in a single cell. For heterozygous carriers, only one allele carries the hypermutable tract, while the other retains the normal sequence and must be inactivated through an independent somatic event. For homozygous carriers, both alleles are hypermutable, potentially increasing the rate at which both hits can occur.

Case reports of homozygous I1307K carriers have documented earlier onset of colorectal neoplasia and higher polyp burden compared to heterozygous carriers, though the extremely small number of documented cases prevents formal risk quantification. The biological principle — two independently hypermutable APC alleles increasing the somatic mutation rate on both chromosomes — is mechanistically sound and warrants a more aggressive surveillance approach than heterozygous carrier management.

AT I1307K Carrier Carrier

One copy of I1307K — hypermutable APC tract increases colorectal cancer risk ~1.5-2 fold

The I1307K variant (c.3920T>A) does not impair the APC protein's tumor suppressor function directly. Instead, the T-to-A change at nucleotide 3920 creates an uninterrupted run of eight adenines (A8) that is inherently difficult for DNA polymerase to replicate faithfully. During each cell division in the colonic epithelium, there is an elevated probability of polymerase slippage at this tract, producing frameshift mutations that truncate APC and remove its brake on Wnt-driven cell proliferation.

Studies have shown that 42% of colorectal tumors from I1307K carriers harbor somatic frameshift mutations originating at the A8 tract — a 10-fold enrichment over the background rate. The risk appears concentrated at the adenoma-to-carcinoma transition: carriers form adenomatous polyps at roughly the same rate as non-carriers, but those polyps are more likely to progress to malignancy.

Meta-analytic data from Ashkenazi Jewish cohorts estimate the odds ratio for colorectal neoplasia at 1.75-2.17, depending on the study population and design. Recent evidence from non-Ashkenazi populations suggests the risk elevation extends to all ethnic groups carrying the variant, with additional associations reported for melanoma and prostate cancer.